anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a medicine for curing appendicitis and the preparation method. The raw materials comprise the following ingredients with corresponding weigh proportions of 6g to 18g of angelica, 4g to 12g of carbonized sanguisorba roots, 4g to 12g of carbonized turtle shell, 4g to 12g of coix seeds, 4g to 12g of carbonized scutellaria roots, 4g to 10g of thistle herb, 3g to 9g of carbonized Chinese honeylocust spine, 4g to 12g of figwort roots, 4g to 10g of liquorice, 10g to 20g of honeysuckle stem and 15g to 25g of dyers woad leaves. The medicine is effective on acute and chronic appendicitis and the effective rate is 100 percent. The effect on the chronic appendicitis is more obvious and the cure rate is 100 percent. Generally speaking, pains are relieved 1 to 2 days after patients take the medicine and the body temperature falls and patient can be cured after one curative period. The medicine is characterized by fast safe curative effect and no nocuous and side effect; moreover, the disease can not recur. In addition, the preparation method of the medicine is simple and the cost is low; patients can be saved from the pains of operation and the economic burden of patient can be reduced. Therefore, the medicine is convenient for application and dissemination. The present invention can play an important role for curing appendicitis.
The present invention concerns the field of diagnostics. Specifically. it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject. said first biomarker being NGAL. determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers. and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being NGAL and a second biomarker selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover. the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
PURPOSE:To manufacture a composite material for organism having merits of both the materials and excellent in wt. and toughness by using Al2O3 as basis particles and Ti as fine particles, covering and joining the basis particles with plural fine particles and forming a capsule granule. CONSTITUTION:Al2O3 (<= about 100mum particle diameter) is made to the basis particles 16 and mechanical alloying is executed to the fine particles 17 of Ti (<= about 10mu particle diameter on the surface of this basis particle 16 and the fine particles are fixed to the basis particle 16 to form the capsule granule 10. Under condition of closely aggregating the capsule granules 10, the fine particles 17 are melted with plasma sintering method, etc., to make base layer 18 integrating mutually the fine particles 17, and the basis particles 16 are dispersed in the base layer 18 to form Al2O3 dispersion type titanium formed body 19. By suitably machining the surface 20 of this formed body 19, artificial bond or root of tooth having affinity to human organism and excellent in wt. and toughness, is obtd.
Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
Ultrasound guidance can enhance existing landmark-based injection methods, even through a brief and single exposure during a cadaveric training course. A total of twelve participants were enrolled in this training program, comprising nine physical medicine and rehabilitation specialists, one pediatrician, and two physician assistants. For each participant, one upper-limb muscle and one lower-limb muscle were randomly chosen from the preselected muscle group. Subsequently, participants were tasked with injecting both of their chosen cadaveric muscles with 1 mL of acrylic paint using a manual needle palpation technique, relying solely on their knowledge of anatomic landmarks. Participants then underwent a personalized, one-to-one ultrasound teaching session, lasting approximately five minutes, conducted by two highly experienced instructors. Following this instructive phase, participants were tasked with a second round of injections, targeting the same two muscles in the lower and upper limbs. However, this time, the injections were performed using anatomical landmarks and ultrasound guidance. To facilitate differentiation from the initial injections, a distinct color of acrylic paint was employed. When employing the anatomical landmark-based approach, the overall success rate for injections was 67%, with 16 out of 24 targeted muscles accurately injected. With the incorporation of ultrasound guidance, the success rate was 92%, precisely targeting 22 out of the 24 muscles under examination. There was an improvement in injection accuracy achievable through the integration of ultrasound guidance, even with minimal training exposure. Our single cadaveric ultra-sound training program contributes valuable insights to the utilization of ultrasound for anatomy training to help optimize the targeting of BoNT-A.
Ferumoxytol was not tested for carcinogenic effects. In standard genotoxicity tests, ferumoxytol showed no evidence of mutagenic activity in an in vitro Ames test or clastogenic activity in either an in vitro chromosomal aberration assay or an in vivo micronucleus assay. 

No adverse effects on fertility or general reproductive performance were noted in animal studies. Ferumoxytol had no effect on male or female fertility or general reproductive function in rats. In a pre and postnatal development study in rats, intravenous administration of ferumoxytol from gestation day 6 until lactation day 20 at doses up to 60 mg/kg/day (approximately 3 times the daily human dose based on body surface area comparisons assuming a 60-kg person) had no effect on maternal delivery or numbers of liveborn offspring. Male offspring (F1) of pregnant rats (F0) administered ferumoxytol at a dose of 60 mg/kg/day had delayed sexual maturation and decreased reproductive competence. Female offspring (F1) of pregnant rats (F0) administered ferumoxytol at doses of 30 mg/kg/day or 60 mg/kg/day had delayed sexual maturation and decreased reproductive competence. Doses of 30 mg/kg/day and 60 mg/kg/day are approximately 2 and 3 times the daily human dose based on body surface area comparisons assuming a 60-kg person, respectively.
A density centrifuge blood processing system with automatic two-dimensional optical control of fluid separation by observing fluid characteristics in observation regions.  The location of the regions is determined by monitoring an optical reference.  Points representing edges of an optical reference are measured and lines are computed through the points. An error measurement is calculated for each line. If the error is too large, the image is abandoned. One of the lines is selected as a referent line. A new line is calculated orthogonal to the referent line. The error function is again computed for the dependant line.  If the error exceeds a selected maximum, the frame is discarded. A  transformation function translates data points from an (r, s) domain derived from measurements of the edges into an (x, y) domain used to identify pixels in the observation areas.
This prospective, double-blind, randomized, sham-controlled clinical trial will investigate the effectiveness of PEMF using the Ivivi SofPulse on postoperative pain severity and narcotic use in women after cesarean delivery at Jacobi Medical Center. On admission to labor and delivery or in the obstetrical outpatient office, potential subjects will complete questions related to inclusion / exclusion criteria and sign a consent to participate in the study. If eligible, patients will receive a Ivivi Sofpulse device which will be placed over the incisional area and turned on. The devices are randomized into functional and sham groups. The device will be left around the incision site unless the patient needs to shower. In an effort to minimize bias, the patients, providers and investigators will not be aware if the device is functional or not. Lot numbers will accompany the device. After completion of the study, the Lot numbers, which will be provided by the manufacturer, will reveal which devices were functional devices or shams. These lot numbers will only be provided on completion of the trial. Wong-Baker Faces pain assessment tool will be evaluated by the Principal Investigator (PI) or co-investigator for determination of subjective postoperative pain at 0, 2, 6, 12, 24, 48, and 72 hours after cesarean delivery. Amount of oxycodone in milligrams consumed by patients will be recorded 24, 48, 72 hours after cesarean delivery. Postoperative anesthesia type (Duramorph or morphine patient controlled anesthesia pump) will be recorded as well. Subjects will be randomized to PEMF treatment (functional), or sham treatment. All subjects will be followed for the duration of their stay in the hospital following their cesarean delivery.

No follow-up is required. The goal is to recruit one hundred patients over the course of four months. Patient data will be identified by use of medical record number and will be kept private on the Jacobi Medical Center Obstetrics and Gynecology server which is password protected. Access will only be for the investigator and co-investigators in the study. Nurse on labor and delivery have already received an in-service on the proper use of this device.
Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
The invention belongs to the field of a pharmaceutical preparation, and relates to a sustained-release microsphere preparation of a goserelin composition and a preparation method of the sustained-release microsphere preparation. Specifically, the goserelin composition includes goserelin and a polypeptide composition capable of enhancing immunity, wherein the polypeptide capable of enhancing immunity comprises thymalfasin, thymopentin and thymosin beta4. The sustained-release microsphere consists of 0.1-40% (w/w) of goserelin and polypeptide capable of enhancing immunity in terms of the total weight of the microsphere, 60-99.9% of a biodegradable and biocompatible high polymer material which is 5,000-200,000Dalton in molecular weight in terms of the weight of the microsphere, and 0-10% of other pharmaceutically acceptable accessories in terms of the weight of the microsphere. The sustained-release microsphere disclosed by the invention is 5-20microns in average grain size and encapsulation efficiency is more than 80%. The sustained-release duration of the sustained-release microsphere can last for several days or several months, so that administration frequency is obviously reduced, bioavailability is improved, the toxic and side effects of medicine are reduced, and the sustained-release microsphere is conducive to clinic treatment. The production process of the finished product is good in reproducibility and good in feasibility.
1,178,294. Tableting lubricant. MILES LABORATORIES Inc. 17 Feb., 1967, No. 7749/67. Heading A5B. Water-effervescent tablets are made by compressing a mixture of a powdered water-effervescent tabletable composition and a tableting lubricant comprising fumaric acid. The effervescent component is a mixture of an alkali metal carbonate or bicarbonate and an acid preferably other than fumaric acid, e.g. malic, citric or tartaric acids. The tablets may contain therapeutically active agents other than the effervescent substances, e.g. analgesics such as acetyl salicylic acid or acetyl p-aminophenol, and conventional binders, disintegrating agents, colouring and flavouring agents.
The invention discloses a melittin-mortiferin hybrid peptide mutant MTM and application thereof, belonging to the technical field of genetic engineering. The invention discloses application of melittin-mortin hybrid peptide mutant MTM in inhibiting activities of escherichia coli, salmonella and staphylococcus aureus. The invention firstly utilizes the SamyX-6His-EDDIE-MTM fusion fragment modified by the bacillus subtilis gene to construct an efficient recombinant bacillus subtilis BSMW expression system for biosynthesis of MTM. MTM was obtained up to 254.38mg from 1L fermentation supernatant. The size of the purified MTM was consistent with the expected molecular weight of 3.2 kDa. MTM has antibacterial activity against Escherichia coli, Salmonella, and Staphylococcus aureus.
Mature haman leukocyte interferons were prepd. by recombinant DNA technol. using Escherichia coli. Thus, mRNAs for interferons A,B,C,D,F,H, and J were isolated from leukocytes and used as substrates for the enzymic synthesis of ds cDNA. These cDNA were inserted, along with a trp control element, into pBR322 and the recombinant plasmid used to transform E, coli K12 strain 294. Interferon polypeptides have no associated glycosyl residues but is may be modified by an N-terminal methionine or a cleavable conjugate or microbial signal protein at the N-terminus. Interferon known for treament of viral infections and malignancies.
OBJECTIVE: Postoperative delirium (POD) is a common complication following off-pump coronary artery bypass grafting (OPCABG) and is associated with significant morbidity. This study aims to evaluate the correlation of systemic immune inflammatory index (SII) and systemic inflammatory response index (SIRI) with postoperative delirium (POD) in patients with cerebral infarction undergoing OPCABG.
METHODS: The perioperative cohort study included 321 patients who underwent OPCABG. Patients were divided into two groups based on the occurrence of POD: the delirium group (n = 113) and the non-delirium group (n = 208). Baseline characteristics, including gender, left ventricular ejection fraction (LVEF), surgery duration, hypertension, age, and smoking history were analyzed. SII and SIRI values were calculated preoperatively, and their association with POD was assessed using univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curves were used to evaluate the predictive accuracy of SII and SIRI.
RESULTS: Statistical differences between SII and SIRI in the two groups (P < 0.05) were observed. Multivariate analysis confirmed that SII and SIRI, age and preoperative smoking history were predictors of POD. ROC curve analysis demonstrated that SII and SIRI had considerable predictive power, with AUC values of 0.73 (0.67-0.79) for SII and 0.75 (0.69-0.81) for SIRI.
CONCLUSION: SII and SIRI were found to be associated with an increased risk of POD in patients undergoing OPCABG, but further research is needed to confirm these findings and determine their independence as risk factors.
Obesity-related chronic low-grade inflammation plays a central role in the development of insulin resistance. Macrophages are key players in adipose tissue homeostasis, and their phenotypic shift from the anti-inflammatory or alternatively activated (M2) form to the pro-inflammatory, classically activated (M1) form is a hallmark of insulin resistance. However, adipose tissue macrophages (ATMs) have been identified as a distinct subpopulation of macrophages in several recent studies. These ATMs, described as metabolically activated macrophages (MMe), differ from M1 and are primarily found in the adipose tissue of obese individuals. In our study, we developed an in vitro model of MMe macrophages to establish a simple and reproducible system to understand their characteristics and role in the pathophysiology of insulin resistance. We examined their characteristics such as inflammatory patterns, surface markers, and metabolic features, and compared them with M1 and M2 macrophages. We found that a cell line-based in vitro model effectively mirrors the characteristics of ATMs, highlighting distinct inflammatory phenotypes, metabolism, surface markers, altered lysosomal activity, and ER stress akin to macrophages in vivo. This model captures the subtle distinctions between MMe and M1, and can be effectively used to study several features of macrophage-adipose interactions of therapeutic importance.
BACKGROUND: Ibrutinib, a Bruton's tyrosine kinase inhibitor used in cancer therapy, exerts ventricular proarrhythmic effects; however, the underlying mechanisms remain unclear. Excitation-contraction coupling (E-C) disorders are pivotal for the genesis of ventricular arrhythmias (VAs), which arise mainly from the right ventricular outflow tract (RVOT). In this study, we aimed to comprehensively investigate whether ibrutinib regulates the electromechanical activities of the RVOT, leading to enhanced arrhythmogenesis, and explore the underlying mechanisms.
METHODS: We utilized conventional microelectrodes to synchronously record electrical and mechanical responses in rabbit RVOT tissue preparations before and after treatment with ibrutinib (10, 50, and 100 nM) and investigated their electromechanical interactions and arrhythmogenesis during programmed electrical stimulation. The fluorometric ratio technique was used to measure intracellular calcium concentration in isolated RVOT myocytes.
RESULTS: Ibrutinib (10-100 nM) shortened the action potential duration. Ibrutinib at 100 nM significantly increased pacing-induced ventricular tachycardia (VT) (from 0% to 62.5%, n = 8, p = 0.025). Comparisons between pacing-induced VT and non-VT episodes demonstrated that VT episodes had a greater increase in contractility than that of non-VT episodes (402.1 ± 41.4% vs. 232.4 ± 29.2%, p = 0.003). The pretreatment of ranolazine (10 μM, a late sodium current blocker) prevented the occurrence of ibrutinib-induced VAs. Ibrutinib (100 nM) increased late sodium current, reduced intracellular calcium transients, and enhanced calcium leakage in RVOT myocytes.
CONCLUSION: Ibrutinib increased the risk of VAs in the RVOT due to dysregulated electromechanical responses, which can be attenuated by ranolazine or apamin.
Parkinson's disease is caused by a selective vulnerability and cell loss of dopaminergic neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine depletion. In Parkinson's disease therapy, dopamine loss is counteracted by the administration of L-DOPA, which is initially effective in ameliorating motor symptoms, but over time leads to a burdening side effect of uncontrollable jerky movements, termed L-DOPA-induced dyskinesia. To date, no efficient treatment for dyskinesia exists. The dopaminergic and serotonergic systems are intrinsically linked, and in recent years, a role has been established for pre-synaptic 5-HT1a/b receptors in L-DOPA-induced dyskinesia. We hypothesized that post-synaptic serotonin receptors may have a role and investigated the effect of modulation of 5-HT4 receptor on motor symptoms and L-DOPA-induced dyskinesia in the unilateral 6-OHDA mouse model of Parkinson's disease. Administration of RS 67333, a 5-HT4 receptor partial agonist, reduces L-DOPA-induced dyskinesia without altering L-DOPA's pro-kinetic effect. In the dorsolateral striatum, we find 5-HT4 receptor to be predominantly expressed in D2R-containing medium spiny neurons, and its expression is altered by dopamine depletion and L-DOPA treatment. We further show that 5-HT4 receptor agonism not only reduces L-DOPA-induced dyskinesia, but also enhances the activation of the cAMP-PKA pathway in striatopallidal medium spiny neurons. Taken together, our findings suggest that agonism of the post-synaptic serotonin receptor 5-HT4 may be a novel therapeutic approach to reduce L-DOPA-induced dyskinesia.
A system including a mobile application and methods of interacting with application users to transmit targeted, individually-curated information based on a user's needs and a calculated experience value index score. The mobile application provides a transparent and secure platform through which authorized users can receive relevant information and provide feedback regarding satisfaction levels. The mobile application receives user feedback and determines the proper information to send to individual application users, the information curated to individual user needs. Observed outcomes scores are compared with expected outcomes scores to calculate an experience value index score, which is analyzed and compared with predetermined threshold values. If a user's experience value index score is above a predetermined threshold, the system transmits routine information to the user. If the user's experience value index score is below the predetermined threshold, the system transmits interactive information to the user to improve user satisfaction.
The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
Hepatectomy is still the treatment of choice for hepatocellular carcinoma, but the prognosis is not agreeable. Part of the patients may present portal vein tumor thrombus (PVTT) after resection. PVTT might further increase the pressure of portal vein and lead to upper gastrointestinal bleeding and worsening of hypersplenism which will endanger the life of the patients. PVTT also plays the centre role of recurrence and metastasis of HCC. There is no standard treatment available now for PVTT yet. TACE is mostly often used to treat the PVTT. We aim to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT.